Division of Gastroenterology and Hepatology, University of Utah, 30 N 1900 E, Salt Lake City, UT 84132, USA.
Department of Pharmacy, Intermountain Medical Center, 5121 South Cottonwood Street, Murray, UT 84107-5701, USA.
Clin Liver Dis. 2016 May;20(2):403-17. doi: 10.1016/j.cld.2015.10.014.
Nonalcoholic fatty liver disease (NAFLD) is prevalent in the general population and a growing indication for liver transplant. Longer wait times and challenges with pretransplant survivorship are expected, underscoring the need for improved management of attendant comorbidities. Recognition with potential modification of obesity, sarcopenia, chronic kidney disease, and cardiovascular disease in patients with NAFLD may have important implications in the pretransplant and posttransplant periods. Although patients with NAFLD have generally favorable postoperative outcomes, they are at risk for developing recurrent disease in their allograft, driving the need for pharmacotherapies and dietary innovations appropriate for use in the posttransplant period.
非酒精性脂肪性肝病（NAFLD）在普通人群中较为普遍，并且是肝移植的一个日益增长的适应证。预计等待时间会延长，移植前的生存率也会面临挑战，这突显了需要改进对并存疾病的管理。在 NAFLD 患者中识别并可能改变肥胖症、肌少症、慢性肾脏病和心血管疾病，可能对移植前和移植后时期具有重要意义。尽管 NAFLD 患者的术后总体结果良好，但他们有在移植物中发生复发性疾病的风险，这需要在移植后时期使用适当的药物治疗和饮食创新。
